Qiagen (QGEN) Rating Reiterated by Goldman Sachs Group

Qiagen (NYSE:QGEN)‘s stock had its “buy” rating reaffirmed by Goldman Sachs Group in a note issued to investors on Tuesday, May 7th, Borsen Zeitung reports.

QGEN has been the topic of a number of other reports. Zacks Investment Research cut shares of Qiagen from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. Jefferies Financial Group reiterated a “neutral” rating on shares of Qiagen in a research report on Monday, January 21st. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a research report on Friday, April 12th. Finally, UBS Group assumed coverage on shares of Qiagen in a research report on Friday, March 15th. They issued a “neutral” rating and a $42.00 price target on the stock. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $41.71.

QGEN stock traded up $0.11 during mid-day trading on Tuesday, reaching $37.87. The company had a trading volume of 749,003 shares, compared to its average volume of 1,409,414. Qiagen has a one year low of $32.33 and a one year high of $41.55. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.52 and a current ratio of 1.69. The stock has a market capitalization of $8.63 billion, a price-to-earnings ratio of 28.26, a PEG ratio of 2.30 and a beta of 0.88.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Qiagen had a net margin of 12.45% and a return on equity of 12.22%. The business had revenue of $348.70 million for the quarter, compared to analysts’ expectations of $351.68 million. During the same period in the previous year, the business earned $0.26 earnings per share. The company’s revenue was up 1.5% on a year-over-year basis. As a group, analysts predict that Qiagen will post 1.43 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the stock. Marshall Wace North America L.P. acquired a new stake in shares of Qiagen during the 1st quarter valued at about $89,000. Marshall Wace LLP acquired a new stake in Qiagen in the 1st quarter worth approximately $16,468,000. Diversified Trust Co acquired a new stake in Qiagen in the 1st quarter worth approximately $922,000. Slow Capital Inc. acquired a new stake in Qiagen in the 1st quarter worth approximately $1,971,000. Finally, FMR LLC lifted its holdings in Qiagen by 2,731.6% in the 1st quarter. FMR LLC now owns 2,548,771 shares of the company’s stock worth $103,518,000 after purchasing an additional 2,458,758 shares during the last quarter. 63.21% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Recommended Story: Consumer Price Index (CPI)

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.